Anticancer peptides
are increasingly being considered as alternative
treatments for cancer due to their potency, selectivity, and low toxicity.
Previously, the peptide LfcinB (21–25)Pal showed in vitro anticancer effects against the Caco-2 colon cancer
cell line (half-maximal inhibitory concentration (IC50):
86 μM). In this study, we developed modifications to the peptide
sequence to increase its anticancer activity. Sequence modifications
were made such as the inclusion of amino hexanoic acid (Ahx), N-terminal
biotinylation, acetylation, and substitutions of Orn for Arg and/or d-Arg by l-Arg. The molecules were synthesized using
manual solid-phase peptide synthesis (SPPS), and their synthetic feasibility
(SAScore) ranged from 6.2 to 7.6. The chromatographic purities of
the synthesized peptides were greater than 89%. We found that Ahx-RWQWRWQWR
and RWQWRWQW-Orn showed activity against both Caco-2 and HT-29 cell
lines and decreased IC50 values by approx. 50% in Caco-2
cells (IC50: 40 μM) when compared to the parent peptide
RWQWRWQWR. Moreover, the modified peptides demonstrated lower hemolytic
effects, with values <10% at 200 μg/mL. Toxicity was assessed
using the Galleria mellonella model and the half-maximal lethal dose
(LD50) for the best peptides was >100 mg/kg, indicating
that their toxicity is classified as moderately toxic or lower. In
contrast, cisplatin showed an LD50 of 13 mg/Kg. The designed
anticancer peptides presented good in vitro activity
and low toxicity, making them promising molecules for future drug
development studies.